Shin Kashimura

Dr. Shin Kashimura

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
TKTakehiro Kimura
Takehiro Kimura
TKTakashi Kohno
Takashi Kohno
KNKazuaki Nakajima
Kazuaki Nakajima
SKShin Kashimura
Shin Kashimura
YKYOSHINORI KATSUMATA
YOSHINORI KATSUMATA
STSeiji Takatsuki
Seiji Takatsuki

1 September 2015 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HHHisayuki Hashimoto
Hisayuki Hashimoto
SYShinsuke Yuasa
Shinsuke Yuasa
HTHidenori Tabata
Hidenori Tabata
STShugo Tohyama
Shugo Tohyama
TSTomohisa Seki
Tomohisa Seki
KFKeiichi Fukuda
Keiichi Fukuda

18 June 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
NHNozomi Hayashiji
Nozomi Hayashiji
SYShinsuke Yuasa
Shinsuke Yuasa
Yuko Miyagoe-SuzukiYuko Miyagoe-Suzuki
Yuko Miyagoe-Suzuki
MHMie Hara
Mie Hara
NINaoki Ito
Naoki Ito
KFKeiichi Fukuda
Keiichi Fukuda
Erratum: G-CSF supports long-term muscle regeneration in mouse models of muscular dystrophy

11 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SKShin Kashimura
Shin Kashimura
NINobuhiro Ikemura
Nobuhiro Ikemura
SKShun Kohsaka
Shun Kohsaka
YKYOSHINORI KATSUMATA
YOSHINORI KATSUMATA
TKTakehiro Kimura
Takehiro Kimura
MIMasaki Ieda
Masaki Ieda
Background: Catheter ablation (CA) benefits atrial fibrillation (AF) patients with heart failure (HF). Brain natriuretic peptide (BNP), a marker of left-ventricular pressure load, may serve as a potential surrogate for predicting quality of life (QOL) in a broader range of patients. Methods: Within the multicenter KiCS-AF registry, 491 AF patients underwent CA without clinical HF (e.g., documented history of HF, left ventricular ejection fraction ≤ 40%, or BNP levels ≥ 100 pg/mL). Participants, aged 61 ± 10 years, were categorized by baseline BNP quartiles. Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire assessments were assessed at baseline and 1 year. Results: A lower baseline BNP correlated with reduced AFEQT scores. Post CA, all groups showed significant AFEQT score improvements. The lower-BNP group displayed notable enhancements (18.2 ± 1.2, 15.0 ± 1.1, 12.6 ± 1.2, 13.6 ± 1.2, p < 0.005), especially in symptom and treatment concern areas. Even those with normal BNP levels (≤18.4 pg/mL) exhibited significant QOL improvements. Comparing paroxysmal AF (PAF) and non-PAF groups, the PAF group, especially with higher BNP levels, showed greater AFEQT score improvements. Conclusions: This study establishes BNP as a predictive marker for QOL enhancement in non-HF patients undergoing CA for AF. BNP levels represent AF stages, with individuals in earlier stages, especially within normal BNP levels, experiencing greater QOL improvements.

23 July 2025 in JACC: Case Reports
Verified
Journal Article
Open access
KTKaho Takuma
Kaho Takuma
SKShin Kashimura
Shin Kashimura
AMAtsushi Matsumoto
Atsushi Matsumoto
KWKota Washimi
Kota Washimi
DSDaisuke Shinmura
Daisuke Shinmura
KNKoji Negishi
Koji Negishi
Malignant tumors of the aortic valve are extremely rare and challenging to diagnose. Here, we present a case of a 59-year-old woman with an intimal sarcoma of the aortic valve that led to acute aortic regurgitation (AR) and recurrent acute coronary syndrome (ACS). The patient initially presented with an out-of-hospital cardiac arrest due to ACS and underwent emergent percutaneous coronary intervention. Despite revascularization and medical therapy, she later developed severe AR and multivessel coronary artery disease, requiring coronary artery bypass grafting (CABG) and aortic valve replacement (AVR). Histopathologic examination confirmed aortic intimal sarcoma, which had remained undiagnosed preoperatively. Although rare, malignant tumors should be considered a potential cause of ACS, particularly in patients with minimal risk factors.

20 December 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
SKShin Kashimura
Shin Kashimura
NINobuhiro Ikemura
Nobuhiro Ikemura
SKShun Kohsaka
Shun Kohsaka
YKYOSHINORI KATSUMATA
YOSHINORI KATSUMATA
TKTakehiro Kimura
Takehiro Kimura
MIMasaki Ieda
Masaki Ieda
Background: Catheter ablation (CA) benefits atrial fibrillation (AF) patients with heart failure (HF). Brain natriuretic peptide (BNP), a marker of left-ventricular pressure load, may serve as a potential surrogate for predicting quality of life (QOL) in broader range of patients. Methods: Within the multicenter KiCS-AF registry, 491 AF patients underwent CA without clinical HF (e.g. documented history of HF, left ventricular ejection fraction ≤40%, or BNP levels ≥100 pg/mL). Participants, aged 61±10 years, were categorized by baseline BNP quartiles. Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire assessments were assessed at baseline and 1 year. Results: Lower baseline BNP correlated with reduced AFEQT scores. Post-CA, all groups showed significant AFEQT score improvements. Lower BNP group displayed notable enhancements (18.2±1.2, 15.0±1.1, 12.6±1.2, 13.6±1.2, p<0.005), especially in symptom and treatment concern areas. Even those with normal BNP levels (≤18.4 pg/ml) exhibited significant QOL improvements. Comparing PAF and non-PAF groups, the PAF group, especially with higher BNP levels, showed greater AFEQT score improvements. Conclusion: This study establishes BNP as a predictive marker for QOL enhancement in non-HF patients undergoing CA for AF. BNP levels represent AF stages, with individuals in earlier stages, especially within normal BNP levels, experiencing greater QOL improvement.